Istituto Europeo Di Oncologia
Istituto Europeo Di Oncologia is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
ETOP 27-23 ARCH – A randomised phase III trial of adjuvant cemiplimab in patients with resected stage IIA-IIIB NSCLC who have not received prior adjuvant chemotherapy.
Sponsor ETOP IBCSG Partners Foundation
- Start (EU)
- Latest update
- Estimated end
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2−) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291)
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer (APTneo)
Sponsor Fondazione Michelangelo
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Istituto Europeo Di Oncologia?
The 2026-10-09 snapshot links Istituto Europeo Di Oncologia to 3 distinct CTIS trials. Recorded services include Biobank, Laboratory services, PDL1 expression test, HER2, hormone receptor assay, Ki67 evaluation, Biobank.. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Istituto Europeo Di Oncologia?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Respiratory. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Istituto Europeo Di Oncologia conducted?
The linked trials record locations in 11 countries, including Germany, Spain, Italy, Austria, Belgium. These are trial locations, not confirmed office locations or countries where Istituto Europeo Di Oncologia delivered services.
What can this page tell me about Istituto Europeo Di Oncologia's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Istituto Europeo Di Oncologia. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Istituto Europeo Di Oncologia S.r.l.